ESSA PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.93 USD | -4.97% |
|
-15.04% | -10.15% |
| Mar. 06 | Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call | |
| Mar. 06 | Norway's wealth fund pushes for more women on emerging market company boards | RE |
Presentation Operator MessageOperator (Operator)Welcome to the Realm Therapeutics conference c...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Calendar
2024-08-12
- Q3 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.114
CAD
Average target price
26.63
CAD
Spread / Average Target
+228.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.15% | 262M | |
| +26.37% | 48.16B | |
| -1.01% | 41.73B | |
| +46.00% | 41.03B | |
| -5.31% | 28.77B | |
| +9.34% | 25.59B | |
| -21.69% | 18.96B | |
| +6.23% | 12.92B | |
| +26.99% | 12.03B | |
| -3.38% | 11.77B |
- Stock Market
- Equities
- EPIX Stock
- News ESSA Pharma Inc.
- Transcript : ESSA Pharma Inc., Realm Therapeutics Plc - M&A Call